Blueprint Medicines Corporation which can be found using ticker (BPMC) have now 17 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 114 and 44 calculating the mean target price we have $71.65. Now with the previous closing price of $54.74 this would imply there is now a potential upside of 30.9%. The 50 day MA is $48.38 and the 200 day MA is $51.89. The market cap for the company is 3.40B. The stock price is currently at: 56.25 USD
The potential market cap would be $4,451,993,342 based on the market consensus.
USD
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 3.42 and a -29.4% return on assets.
